Related Experiment Video
Updated: May 5, 2026
07:22
Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
Published on: March 28, 2013
38.4K
Hepatic failure in a patient taking rosiglitazone
L M Forman1, D A Simmons, R H Diamond
1Division of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia 19104, USA.
Annals of Internal Medicine
|January 22, 2000
Summary
A patient developed severe liver failure after taking rosiglitazone, a diabetes medication. Prompt discontinuation and supportive care led to a full recovery, suggesting a potential link between rosiglitazone and hepatotoxicity.
Area of Science:
- Hepatology
- Pharmacology
- Internal Medicine
Background:
- Rosiglitazone is a thiazolidinedione class oral hypoglycemic agent.
- Previous thiazolidinedione, troglitazone, was linked to liver failure.
- No prior reports linked rosiglitazone to hepatotoxicity or elevated liver enzymes.
Observation:
- A case report details a 69-year-old male patient on rosiglitazone therapy.
- The patient developed hepatic failure after 21 days of treatment.
- Other causes of liver failure were ruled out.
Findings:
- The patient experienced severe liver failure during rosiglitazone treatment.
- Supportive care, including drug discontinuation, resulted in complete recovery.
- Congestive heart failure was a potential contributing factor.
Implications:
- This case suggests a potential association between rosiglitazone and drug-induced liver injury.
- Further investigation into rosiglitazone's hepatotoxicity is warranted.
- Physicians should monitor patients for liver function during rosiglitazone therapy.
More Related Videos
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
382
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
379
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
993
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
993
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
01:29Hyperglycemia
25
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose...
25
01:27Diabetic Retinopathy
55
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
55